Medivir AB (publ) (MVRBF) Stock Price, News & Analysis

Company Overview

Medivir AB (publ) is a Sweden-based clinical-stage biotechnology company focused on developing treatments for cancer. The company’s research is centered on targeted therapies designed to address significant unmet medical needs, particularly in oncology.

Medivir’s lead product candidate is fostroxacitabine bralpamide, also known as fostrox, an orally administered, liver-directed chemotherapy designed to deliver its active drug selectively to tumor cells in the liver. The candidate has been studied primarily in patients with hepatocellular carcinoma, the most common form of primary liver cancer, including in combination with other cancer treatments.

Medivir conducts research and clinical development activities in collaboration with healthcare and life sciences partners. The company is headquartered in Sweden and has historically developed antiviral and oncology-focused drug candidates, with its more recent efforts concentrated on cancer therapies. Further information about current management and geographic operations may change as the company’s development programs evolve.

Key Stats

• Today's Range: $0.82 to $0.82
• 50-Day Range: $0.82 to $0.82
• 52-Week Range: $0.68 to $0.82
• Volume: N/A
• Average Volume: 925 shs
• Market Capitalization: N/A
• P/E Ratio: 0.03
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:MVRBF
• CIK: N/A
• Web: www.medivir.com
• Phone: (685) 468-3100
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 0.03
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A